MX2017008248A - Metodo de tratamiento. - Google Patents
Metodo de tratamiento.Info
- Publication number
- MX2017008248A MX2017008248A MX2017008248A MX2017008248A MX2017008248A MX 2017008248 A MX2017008248 A MX 2017008248A MX 2017008248 A MX2017008248 A MX 2017008248A MX 2017008248 A MX2017008248 A MX 2017008248A MX 2017008248 A MX2017008248 A MX 2017008248A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- hfpef
- cardiotonic
- pyridinyl
- sustained
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 abstract 2
- NHWKTZWOSIVHOL-UHFFFAOYSA-N 5-pyridin-2-yl-1h-pyridin-2-one Chemical class N1C(=O)C=CC(C=2N=CC=CC=2)=C1 NHWKTZWOSIVHOL-UHFFFAOYSA-N 0.000 abstract 1
- 230000003177 cardiotonic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014905194A AU2014905194A0 (en) | 2014-12-22 | Method of Treatment | |
| PCT/AU2015/050820 WO2016101024A1 (en) | 2014-12-22 | 2015-12-21 | Method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008248A true MX2017008248A (es) | 2018-02-19 |
Family
ID=56148784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008248A MX2017008248A (es) | 2014-12-22 | 2015-12-21 | Metodo de tratamiento. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10493067B2 (enExample) |
| EP (1) | EP3236963B1 (enExample) |
| JP (2) | JP2018500365A (enExample) |
| KR (1) | KR20170098897A (enExample) |
| CN (1) | CN107530337B (enExample) |
| AU (1) | AU2015372434B2 (enExample) |
| BR (1) | BR112017013015A2 (enExample) |
| CA (1) | CA2971071A1 (enExample) |
| EA (1) | EA201791455A1 (enExample) |
| IL (1) | IL253028B (enExample) |
| MX (1) | MX2017008248A (enExample) |
| SG (1) | SG11201704980XA (enExample) |
| WO (1) | WO2016101024A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017008248A (es) * | 2014-12-22 | 2018-02-19 | Cardiora Pty Ltd | Metodo de tratamiento. |
| US11730733B2 (en) | 2020-12-10 | 2023-08-22 | Imbria Pharmaceuticals, Inc. | Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine |
| US11793807B2 (en) | 2020-12-10 | 2023-10-24 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine |
| WO2022125370A1 (en) * | 2020-12-10 | 2022-06-16 | Imbria Pharmaceuticals, Inc. | Methods of treating heart conditions using modified forms of trimetazidine |
| US11969422B2 (en) | 2020-12-10 | 2024-04-30 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine |
| US12076318B2 (en) | 2020-12-10 | 2024-09-03 | Imbria Pharmaceuticals, Inc. | Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4297360A (en) | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
| US4313951A (en) | 1979-11-26 | 1982-02-02 | Sterling Drug Inc. | 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor |
| IL61501A (en) | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| US5009895A (en) | 1990-02-02 | 1991-04-23 | Merck & Co., Inc. | Sustained release with high and low viscosity HPMC |
| US5213811A (en) | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
| SK279684B6 (sk) | 1993-06-14 | 1999-02-11 | Janssen Pharmaceutica N.V. | Tableta a spôsob jej výroby |
| US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
| GB9402203D0 (en) | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
| US7214387B2 (en) | 2002-08-02 | 2007-05-08 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
| KR100548925B1 (ko) | 2002-10-23 | 2006-02-02 | 한미약품 주식회사 | 약물의 경구투여용 서방성 조성물 |
| US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
| US20050095292A1 (en) | 2003-10-29 | 2005-05-05 | Wyeth | Sustained release pharmaceutical compositions |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| EP2432470A1 (en) * | 2009-05-20 | 2012-03-28 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
| WO2013002350A1 (ja) * | 2011-06-29 | 2013-01-03 | 京都府公立大学法人 | 腫瘍部位の識別装置及び識別方法 |
| AU2012297569B2 (en) * | 2011-08-16 | 2017-11-09 | Baker Heart and Diabetes Institute | Controlled-release formulation |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
| WO2013116194A2 (en) * | 2012-01-30 | 2013-08-08 | O'connell Timothy D | Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis |
| MX2017008248A (es) * | 2014-12-22 | 2018-02-19 | Cardiora Pty Ltd | Metodo de tratamiento. |
-
2015
- 2015-12-21 MX MX2017008248A patent/MX2017008248A/es unknown
- 2015-12-21 BR BR112017013015A patent/BR112017013015A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN201580076215.4A patent/CN107530337B/zh active Active
- 2015-12-21 WO PCT/AU2015/050820 patent/WO2016101024A1/en not_active Ceased
- 2015-12-21 CA CA2971071A patent/CA2971071A1/en active Pending
- 2015-12-21 KR KR1020177020214A patent/KR20170098897A/ko not_active Withdrawn
- 2015-12-21 SG SG11201704980XA patent/SG11201704980XA/en unknown
- 2015-12-21 EP EP15871347.9A patent/EP3236963B1/en active Active
- 2015-12-21 EA EA201791455A patent/EA201791455A1/ru unknown
- 2015-12-21 AU AU2015372434A patent/AU2015372434B2/en active Active
- 2015-12-21 US US15/538,123 patent/US10493067B2/en active Active
- 2015-12-21 JP JP2017534610A patent/JP2018500365A/ja not_active Revoked
-
2017
- 2017-06-20 IL IL253028A patent/IL253028B/en active IP Right Grant
-
2019
- 2019-12-02 US US16/700,237 patent/US11291660B2/en active Active
-
2021
- 2021-12-24 JP JP2021210184A patent/JP7475324B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022163681A (ja) | 2022-10-26 |
| US20170348292A1 (en) | 2017-12-07 |
| IL253028A0 (en) | 2017-08-31 |
| NZ732954A (en) | 2021-11-26 |
| IL253028B (en) | 2019-12-31 |
| US11291660B2 (en) | 2022-04-05 |
| EP3236963B1 (en) | 2020-01-29 |
| BR112017013015A2 (pt) | 2018-03-06 |
| US10493067B2 (en) | 2019-12-03 |
| KR20170098897A (ko) | 2017-08-30 |
| AU2015372434B2 (en) | 2018-10-04 |
| CN107530337B (zh) | 2021-07-09 |
| CN107530337A (zh) | 2018-01-02 |
| JP2018500365A (ja) | 2018-01-11 |
| EA201791455A1 (ru) | 2017-12-29 |
| WO2016101024A1 (en) | 2016-06-30 |
| EP3236963A1 (en) | 2017-11-01 |
| JP7475324B2 (ja) | 2024-04-26 |
| EP3236963A4 (en) | 2018-08-08 |
| CA2971071A1 (en) | 2016-06-30 |
| SG11201704980XA (en) | 2017-07-28 |
| AU2015372434A1 (en) | 2017-07-13 |
| US20200101053A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3171786A4 (en) | Devices and methods for treating heart failure | |
| IL257175A (en) | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | |
| IL256501B (en) | Causes, uses and methods of treating synuclein pathology | |
| IL247450A0 (en) | Aryl, heteroaryl, and heterocyclic compounds for the treatment of complement-mediated disorders | |
| EP3206613A4 (en) | Method and apparatus for rapid and safe pulmonary vein cardiac ablation | |
| HK1245019A1 (zh) | 吡啶酰胺化合物作爲杀真菌剂的用途 | |
| WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
| MX2017008248A (es) | Metodo de tratamiento. | |
| EP3188734A4 (en) | Method of treating organophosphate intoxication | |
| EP3305274A4 (en) | Preparation containing ergothioneine, preparation method thereof and use of mushroom extracellular ferment liquor | |
| SG11201705450SA (en) | Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases | |
| EP3094328A4 (en) | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone | |
| ZA202002292B (en) | Methods of treating heart failure with preserved ejection fraction | |
| EP3262021A4 (en) | Treatment method, compounds, and method of increasing trpv2 activity | |
| SG10202008024VA (en) | Method for Treating Heart Failure | |
| IN2014MU00675A (enExample) | ||
| EP3256137A4 (en) | Method of treating heart failure | |
| HK1255221A1 (zh) | 使用卡多曲组合物进行治疗的方法 | |
| EP3281243A4 (en) | Method of treating carbon electrode | |
| EP3089725A4 (en) | Method and system for heart pacing | |
| ZA201700972B (en) | Process for the recovery of carboxylic acid and wood treatment process | |
| GB201514302D0 (en) | Lactobacilli for treating cardiac dysfunction | |
| HRP20181123T1 (hr) | Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac | |
| GB201415090D0 (en) | Method for treatment of tools and tools used for isolation of microvesicles, nanovescicles or exsomes | |
| AU2014905243A0 (en) | Method for treating heart failure |